tetano
Editor, Senior Moderator
J Hypertens
. 2022 Feb 25.
doi: 10.1097/HJH.0000000000003110. Online ahead of print.
Cardiovascular outcome 6 months after severe coronavirus disease 2019 infection
Anne G Raafs[SUP] 1 [/SUP], Mohammed A Ghossein, Yentl Brandt, Michiel T H M Henkens, M Eline Kooi, Kevin Vernooy, Marc E A Spaanderman, Suzanne Gerretsen, Susanne van Santen, Rob G H Driessen, Christian Knackstedt, Iwan C C van der Horst, Bas C T van Bussel, Stephane R B Heymans, Chahinda Ghossein-Doha, MaastrICCht collaborators
Affiliations
Abstract
Objectives: In coronavirus disease 2019 (COVID-19), cardiovascular risk factors and myocardial injury relate to increased mortality. We evaluated the extent of cardiac sequelae 6 months after hospital discharge in patients surviving ICU hospitalization for COVID-19.
Methods: All survivors of Maastricht-ICU were invited for comprehensive cardiovascular evaluation 6 months after discharge from ICU. Cardiac screening included an electrocardiogram, cardiac biomarkers, echocardiography, cardiac magnetic resonance (CMR) and, wherever indicated, cardiac computed tomography or coronary angiogram.
Results: Out of 52 survivors, 81% (n = 42) participated to the cardiovascular follow-up [median follow-up of 6 months, interquartile range (IQR) 6.1-6.7]. Eight patients (19%) had newly diagnosed coronary artery disease (CAD), of which two required a percutaneous intervention. Echocardiographic global longitudinal strain (GLS) was abnormal in 24% and CMR-derived GLS was abnormal in 12%, despite normal left ventricular ejection fraction in all. None of the patients showed elevated T1 relaxation times and five patients (14%) had an elevated T2 relaxation time. Late gadolinium enhancement (LGE) reflecting regional myocardial fibrosis was increased in eight patients (21%), of which three had myocarditis and three had pericarditis.
Conclusion: Cardiovascular follow-up at 6 months after ICU-admission for severe COVID-19 revealed that one out of five invasively mechanically ventilated survivors had CAD, a quarter had subclinical left ventricular dysfunction defined as reduced echocardiographic GLS, and 42% of the patients had CMR abnormalities (reduced LVEF, reduced GLS, LGE presence, and elevated T2). On the basis of these findings, long-term cardiovascular follow-up is strongly recommended in all post-IC COVID-19 patients.
Clinical trial registration: Trial Register number [NL8613]) https://www.trialregister.nl/trial/8613.
Video abstract: http://links.lww.com/HJH/B899.
. 2022 Feb 25.
doi: 10.1097/HJH.0000000000003110. Online ahead of print.
Cardiovascular outcome 6 months after severe coronavirus disease 2019 infection
Anne G Raafs[SUP] 1 [/SUP], Mohammed A Ghossein, Yentl Brandt, Michiel T H M Henkens, M Eline Kooi, Kevin Vernooy, Marc E A Spaanderman, Suzanne Gerretsen, Susanne van Santen, Rob G H Driessen, Christian Knackstedt, Iwan C C van der Horst, Bas C T van Bussel, Stephane R B Heymans, Chahinda Ghossein-Doha, MaastrICCht collaborators
Affiliations
- PMID: 35221322
- DOI: 10.1097/HJH.0000000000003110
Abstract
Objectives: In coronavirus disease 2019 (COVID-19), cardiovascular risk factors and myocardial injury relate to increased mortality. We evaluated the extent of cardiac sequelae 6 months after hospital discharge in patients surviving ICU hospitalization for COVID-19.
Methods: All survivors of Maastricht-ICU were invited for comprehensive cardiovascular evaluation 6 months after discharge from ICU. Cardiac screening included an electrocardiogram, cardiac biomarkers, echocardiography, cardiac magnetic resonance (CMR) and, wherever indicated, cardiac computed tomography or coronary angiogram.
Results: Out of 52 survivors, 81% (n = 42) participated to the cardiovascular follow-up [median follow-up of 6 months, interquartile range (IQR) 6.1-6.7]. Eight patients (19%) had newly diagnosed coronary artery disease (CAD), of which two required a percutaneous intervention. Echocardiographic global longitudinal strain (GLS) was abnormal in 24% and CMR-derived GLS was abnormal in 12%, despite normal left ventricular ejection fraction in all. None of the patients showed elevated T1 relaxation times and five patients (14%) had an elevated T2 relaxation time. Late gadolinium enhancement (LGE) reflecting regional myocardial fibrosis was increased in eight patients (21%), of which three had myocarditis and three had pericarditis.
Conclusion: Cardiovascular follow-up at 6 months after ICU-admission for severe COVID-19 revealed that one out of five invasively mechanically ventilated survivors had CAD, a quarter had subclinical left ventricular dysfunction defined as reduced echocardiographic GLS, and 42% of the patients had CMR abnormalities (reduced LVEF, reduced GLS, LGE presence, and elevated T2). On the basis of these findings, long-term cardiovascular follow-up is strongly recommended in all post-IC COVID-19 patients.
Clinical trial registration: Trial Register number [NL8613]) https://www.trialregister.nl/trial/8613.
Video abstract: http://links.lww.com/HJH/B899.